Mounjaro: the version I wish someone had shown me in week 1
Mounjaro: the version I wish someone had shown me in week 1, logged the same way every week so the comparison is at least internally fair.
The step schedule question, answered properly, because it comes up weekly.
The label sets a minimum interval of four weeks between increases. That is a floor on how fast you may go, and it exists because tolerability, not efficacy, is what limits most people. There is nothing in the pharmacology that says you must increase at four weeks, or at eight, or ever.
What decides it in practice is whether the effect you want is still there. If appetite is quiet and the trend is going the right way, the dose is doing its job. If both have genuinely gone flat for six weeks or more, that is a conversation worth having with someone who knows your history.
The thing nobody warned me about was how much of this is logistics — storing it, remembering it, the same day every week.
Corrections welcome, especially the pedantic ones. Pedantry is how this board earns its reputation.
best — the order this archive was captured in
Switching from semaglutide, since three people asked in this thread alone.
There is no published dose equivalence between the two. The conversion tables that circulate are somebody’s arithmetic, not data. What people report here is that the first month after a switch is often flat, that the appetite effect feels differently shaped rather than simply stronger, and that starting at the bottom of the ladder again is the common approach.
None of that is a recommendation. It is what the threads say, and the threads are not a clinic.
Left up, flair changed to Discussion. It is an opinion post and that is fine as long as it is labelled.
Left up, flair changed to Discussion.
Agreed, with one qualifier: that is the mean of the top arm and the spread around it was enormous.
It is a dual GIP and GLP-1 receptor agonist, and the GIP arm is the part that has no equivalent in the semaglutide threads. That is why the side-effect profile reads differently rather than just milder.
Small fix: SURMOUNT is the obesity programme, SURPASS is the type-2 programme. They are different endpoints and the numbers do not transfer.
12kg over 72 weeks, never went past 10mg, and early fullness stayed mild the whole way. Posting because the loud threads are all 15mg.
Pen or vial? The step sizes available differ and it changes this answer.
SURMOUNT-1 ran 72 weeks with the top arm around 21% mean body weight change. SURPASS is the diabetes programme and reports glycaemic endpoints, so quoting the two interchangeably is a category error.
Research-use-only material is not approved for human use. Anything in this thread about how a research vial "should" titrate is a discussion about chemistry, not a plan.
That percentage is body weight change, not body fat. Different measurement, and the distinction gets lost every time.
Sulphur burps for the first eight days after each step, then nothing. Predictable enough that I planned my week around it.
switching from sema is not a dose conversion, there is no clean equivalence
2.5mg is a four-week starting dose, not a maintenance dose. Worth being precise since people search these threads.
The 21% figure is a 72-week mean on the highest arm. Quoting it as what someone should expect by week 39 is not a fair reading.
pens and vials are the same molecule, the price is the difference
[removed by moderator]
Careful with "everyone tolerates it better". The people it did not suit stop posting, which makes this board look calmer than the drug is.
- 1Switching from semaglutide, since three people asked in this thread alone.…7 comments in this branch · started by u/customs_seizure_sid